Targeted disruption of EBNA1 in EBV-infected cells attenuated cell growth
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Epstein Barr virus (EBV)-encoded nuclear antigen-1 (EBNA1) plays a pivotal in an EBV episome replication and persistence. Despite considerable attempts, there are no EBV drugs or vaccines. We attempted to eradicate EBV episomes by targeting EBNA1 using the transcription activator-like effector nucleases (TALEN) (E1TN). E1TN-mediated transient knockout (KO) of EBNA1 reduced EBNA1 expression, and caused significant loss of EBV genomes and progressive death of EBV-infected cells. Furthermore, when a mixture of EBV-infected Burkitt’s lymphoma (BL) cells and EBV-negative BL cells was targeted by E1TN, EBV-negative cells were counter-selected while most EBV-infected cells died, further substantiating that EBNA1 KO caused selective death of EBV-infected cells. TALEN-mediated transient targeting of EBNA1 attenuated the growth of EBV-infected cells, implicating a possible therapeutic application of E1TN for EBV-associated disorders.
Abstract
Epstein Barr virus (EBV)-encoded nuclear antigen-1 (EBNA1) plays a pivotal in an EBV episome replication and persistence. Despite considerable attempts, there are no EBV drugs or vaccines. We attempted to eradicate EBV episomes by targeting EBNA1 using the transcription activator-like effector nucleases (TALEN) (E1TN). E1TN-mediated transient knockout (KO) of EBNA1 reduced EBNA1 expression, and caused significant loss of EBV genomes and progressive death of EBV-infected cells. Furthermore, when a mixture of EBV-infected Burkitt’s lymphoma (BL) cells and EBV-negative BL cells was targeted by E1TN, EBV-negative cells were counter-selected while most EBV-infected cells died, further substantiating that EBNA1 KO caused selective death of EBV-infected cells. TALEN-mediated transient targeting of EBNA1 attenuated the growth of EBV-infected cells, implicating a possible therapeutic application of E1TN for EBV-associated disorders.
참고문헌 (21)
- Parkin DM, "The global health burden of infectionassociated cancers in the year 2002", Int J Cancer, 118, pp.3030~3044 (2006)
- Granato M, "Deletion of Epstein-Barr virus BFLF2 leads to impaired viral DNA packaging, primary egress as well as to the production of defective viral particles", J Virol, 82, pp.4042~4051 (2008)
- Adams A, "Epstein-Barr virus genomes with properties of circular DNA molecules in carrier cells", Proc Natl Acad Sci U S A, 72, pp.1477~1481 (1975)
- Raynaud FI, "In vitro, in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine, CYC202", Clin Cancer Res, 11, pp.4875~4887 (2005)
- Henderson A, "Chromosome site for Epstein-Barr virus DNA in a Burkitt tumor cell line, in lymphocytes growth-transformed in vitro", Proc Natl Acad Sci U S A, 80, pp.1987~1991 (1983)
- Matsuo T, "Persistence of the entire Epstein-Barr virus genome integrated into human lymphocyte DNA", Science, 226, pp.1322~1325 (1984)
- Sugden B, "A vector that replicates as a plasmid, can be efficiently selected in B-lymphoblasts transformed by Epstein-Barr virus", Mol Cell Biol, 5, pp.410~413 (1985)
- Yates JL, "Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells", Nature, 313, pp.812~815 (1985)
- Kang MS, "Roscovitine inhibits EBNA1 serine 393 phosphorylation, nuclear localization, transcription, , episome maintenance", J Virol, 85, pp.2859~2868 (2011)
- Kang MS, "Epstein-Barr virus nuclear antigen 1 activates transcription from episomal but not integrated DNA, does not alter lymphocyte growth", Proc Natl Acad Sci U S A, 98, pp.15233~15238 (2001)
- Nasimuzzaman M, "Eradication of epstein-barr virus episome, associated inhibition of infected tumor cell growth by adenovirus vector-mediated transduction of dominant-negative EBNA1", Mol Ther, 11, pp.578~590 (2005)
- Yin Q, "siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function, growth of EBV-dependent tumor cells", Virology, 346, pp.385~393 (2006)
- Miller JC, "A TALE nuclease architecture for efficient genome editing", Nat Biotechnol, 29, pp.143~148 (2011)
- Kim SY, "Small molecule, peptide-mediated inhibition of Epstein-Barr virus nuclear antigen 1 dimerization", Biochem Biophys Res Commun, 424, pp.251~256 (2012)
- Lee EK, "Small molecule inhibition of Epstein-Barr virus nuclear antigen-1 DNA binding activity interferes with replication, persistence of the viral genome", Antiviral Res, 104C, pp.73~83 (2014)
- Cohen JI, "The need, challenges for development of an Epstein-Barr virus vaccine", Vaccine, 31(Suppl 2), pp.B194~B196 (2013)
- Kim Y, "A library of TAL effector nucleases spanning the human genome", Nat Biotechnol, 31, pp.251~258 (2013)
- Sung YH, "Knockout mice created by TALEN-mediated gene targeting", Nat Biotechnol, 31, pp.23~24 (2013)
- Young Hoon Sung, "Mouse genetics: Catalogue and scissors", BMB Reports, 45(12), pp.686~692 (2012), 생화학분자생물학회
- Molesworth SJ, "Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells", J Virol, 74, pp.6324~6332 (2000)
- 박주원, "Establishment and characterization of bortezomib-resistant U266 cell line: Constitutive activation of NF-κB-mediated cell signals and", or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis, 2014, pp.47(5), 274~279[DOI]